Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161635 · ClinicalTrials.gov registry record · NA
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
A NA study of Presbyopia and Aphakia, sponsored by Alcon Research.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 5
- Study locations
NCT07161635: Recruiting NA study of Presbyopia and Aphakia, sponsored by Alcon Research.
NCT07161635 is a NA study of Presbyopia and Aphakia that is actively recruiting participants, run by Alcon Research. The registered enrollment target is 120 participants, below the 267-participant average among 38 other Presbyopia trials with a reported enrollment target (55% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07161635, a NA study of Presbyopia and Aphakia, is actively recruiting participants, sponsored by Alcon Research.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to collect safety and performance data on two approved intraocular lenses (IOLs). This study will be conducted in participants who require cataract surgery in both eyes. The IOLs are designed to provide vision at far, arm's length, and near.
Primary Outcome
Visual Acuity (VA) will be assessed for both eyes together (binocular) using Early Treatment Diabetic Retinopathy Study (ETDRS) reading charts at a distance of 4 meters from the subject under photopic (well-lit) conditions with correction in place. BCDVA will be measured in logarithm Minimum Angle of Resolution (logMAR). LogMAR values typically range from -0.3 (20/10 vision on the Snellen chart) to 1 (20/200 vision), with lower scores indicating better vision.
Conditions Studied
Interventions
- DEVICE Clareon PanOptix Pro/Pro Toric Trifocal IOL
- PROCEDURE Phacoemulsification
Study Locations (5)
California
- Wolstan & Goldberg Eye Associates - Torrance
Missouri
- Moyes Eye Center - Kansas City
South Carolina
- Carolina Eyecare Physicians LLC - Mt. Pleasant
Texas
- Houston Eye Associates - Houston
Utah
- The Eye Institute of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT07161635 shows while recruiting
NCT07161635 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 267-participant average among 38 other Presbyopia trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Presbyopia appearing as the primary indexed condition, and to 2 interventions - of which Clareon PanOptix Pro/Pro Toric Trifocal IOL is the first listed.
NCT07161635 lists 5 locations in 5 states (California, Missouri, South Carolina).
Frequently Asked Questions
What is clinical trial NCT07161635 about?
NCT07161635 is a clinical study titled "Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs". The purpose of this study is to collect safety and performance data on two approved intraocular lenses (IOLs). This study will be conducted in participants who require cataract surgery in both eyes. The IOLs are designed to provide vision at far, arm's length, and near.
What is the current status of trial NCT07161635?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-10-14. Estimated completion is 2026-10.
What conditions does trial NCT07161635 study?
This clinical trial studies the following conditions: Presbyopia, Aphakia.
What interventions are being tested in trial NCT07161635?
The interventions under investigation include: Clareon PanOptix Pro/Pro Toric Trifocal IOL (DEVICE), Phacoemulsification (PROCEDURE).
Who is sponsoring clinical trial NCT07161635?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161635 being conducted?
This trial has 5 study locations across California, Missouri, South Carolina, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07161635's enrollment target sits among peer trials
120 14th of 38 higher than 25 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Presbyopic Wear Experience With Multifocal Lenses Compared to Single Vision Lenses and Reading Glasses
RECRUITING · NA
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
ACTIVE NOT RECRUITING · NA
-
Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
COMPLETED · NA
-
A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI